Does Insulin Resistance Predict Lower Urinary Tract Symptoms? Results From the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial
Key Points
This research aims to determine if insulin resistance is a predictor of urinary tract symptoms in patients with prostate cancer.
Analysis of data from the REDUCE trial
Assessment of insulin resistance's relationship with urinary tract symptoms
Evaluation of prostate volume measurements
Insulin resistance was associated with larger prostate volumes
Insulin resistance was not an independent risk factor for the development of urinary tract symptoms
No significant link between insulin resistance and LUTS progression observed
Abstract
Although IR was linked to larger prostate volumes, it was not an independent risk factor of LUTS development or progression despite the known associations between BPH and LUTS.